Human epidermal growth factor receptor 2 (HER2) was first recognized as an oncogene contributing to the pathogenesis of breast cancer and is a well-established therapeutic target for breast and an increasing number of gastrointestinal cancers [91]. The gene discussed is ERBB2; the disease is breast cancer.